Gentherm Announces FDA 510(k) Submission for Innovative Technology Expected to Promote Safer Surgeries and Better Patient Outcomes

Rhea-AI Summary

Gentherm (NASDAQ: THRM) submitted a 510(k) Class II premarket notification to the U.S. Food and Drug Administration on Feb. 3, 2026 for ThermAffyx™ Patient Safety System, an integrated patient warming and securement device. The company plans a market launch in the third quarter of 2026.

The ThermAffyx system combines air-free warming with securement to address intraoperative hypothermia and patient movement in procedures using Trendelenburg positioning. FDA clearance is expected in the first half of 2026, and the product adapts thermal technology from Gentherm’s automotive business for medical use.

Positive

• Submitted FDA 510(k) Class II premarket notification for ThermAffyx
• Planned market launch in Q3 2026
• First-of-its-kind integrated warming and securement addressing hypothermia and movement
• Leverages automotive thermal technology for medical application

Negative

• FDA clearance pending; expected H1 2026 but not guaranteed
• No financial guidance or revenue impact disclosed for ThermAffyx
• Clinical benefit claims depend on future clearance and real-world adoption

News Market Reaction – THRM

-1.79%

7 alerts

-1.79% Session close to close

$1.01B Market Cap

0.2x Rel. Volume

In the Feb 3 session, THRM declined 1.79%, reflecting a mild negative market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement underscores Gentherm’s effort to extend its thermal management expertise into medi...

Analysis

This announcement underscores Gentherm’s effort to extend its thermal management expertise into medical settings via the ThermAffyx Patient Safety System. The 510(k) Class II submission and expected FDA clearance in the first half of 2026 point to a defined regulatory path, with a launch targeted for the third quarter. Investors can track progress alongside the previously announced Modine combination, focusing on execution, integration and how new medical revenues complement core automotive operations.

Key Figures

FDA clearance timeline: first half of 2026 Planned product launch: third quarter of this year

2 metrics

FDA clearance timeline first half of 2026 Expected timing for 510(k) clearance of ThermAffyx Patient Safety System

Planned product launch third quarter of this year Target market launch for ThermAffyx patient warming and securement system

Historical Context

5 past events · Latest: Jan 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 29	Strategic combination	Positive	-0.6%	Announced Reverse Morris Trust combination with Modine’s Performance Technologies unit.
Nov 04	Conference participation	Neutral	-1.8%	Planned fireside chat at Baird Global Industrial Conference in Chicago.
Oct 23	Earnings results	Positive	+8.2%	Reported record Q3 2025 revenue and strong new automotive business awards.
Oct 08	Earnings scheduling	Neutral	-1.9%	Announced date and call details for upcoming Q3 2025 earnings release.
Aug 04	Investor conferences	Neutral	+1.4%	Outlined participation in J.P. Morgan Auto and Seaport investor conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Operational and earnings updates have generally seen aligned positive reactions, while the recent large strategic combination drew a mild negative divergence, indicating some market caution around transformative deals.

Recent Company History

Over the past six months, Gentherm reported record Q3 2025 results with strong revenue and new automotive awards, which coincided with a solid positive price reaction. The company also maintained active investor engagement through multiple conferences. More recently, Gentherm announced a Reverse Morris Trust combination with Modine’s Performance Technologies, creating a larger thermal management platform; that strategic news saw a small negative move, suggesting investors weighed integration and deal risk carefully. Today’s FDA 510(k) submission continues a thread of expanding beyond automotive into medical applications.

Key Terms

510(k), premarket notification, u.s. food and drug administration, trendelenburg, +1 more

5 terms

510(k) regulatory

"announced it submitted a 510(k) Class II premarket notification to the U.S. Food"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

premarket notification regulatory

"submitted a 510(k) Class II premarket notification to the U.S. Food and Drug"

A premarket notification is a regulatory submission companies send to a health authority (for example, the U.S. Food and Drug Administration) to show a medical device is similar enough to an existing, approved product to be marketed. For investors, clearance from a premarket notification is like getting a green light to sell a product — it reduces regulatory uncertainty, shortens time to revenue, and lowers the risk that a new device will be blocked or delayed.

u.s. food and drug administration regulatory

"premarket notification to the U.S. Food and Drug Administration (FDA) for ThermAffyx"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

trendelenburg medical

"procedures where it is common for the patient to be positioned in Trendelenburg."

A Trendelenburg position is a medical posture where a person lies on their back with the body tilted so the head is lower than the feet, like raising one end of a flat board. Clinically it is used during some surgeries, exams and procedures to improve blood flow or access; investors should note it because its use can affect device design, procedure risk profiles, clinical trial protocols and regulatory or reimbursement considerations.

hypothermia medical

"warming with securement technology to help prevent both hypothermia and patient"

Hypothermia is a medical condition where the body’s core temperature falls below the level needed to keep organs and systems working properly, like a machine slowing down when it runs too cold. For investors, hypothermia matters because treatments, medical devices, drug development, hospital protocols, and regulatory approvals tied to managing or preventing low body temperature can affect healthcare costs, company revenues, and the commercial prospects of therapies or products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Market launch for its first of a kind integrated patient warming and securement system planned for third quarter of this year

NOVI, Mich., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM) a global market leader of innovative thermal management and pneumatic comfort technologies, today announced it submitted a 510(k) Class II premarket notification to the U.S. Food and Drug Administration (FDA) for ThermAffyx™ Patient Safety System, an integrated patient warming and securement system.

Two leading patient safety concerns during robotic surgery are maintaining patient temperature and preventing patient movement while on the operating room table. The first of its kind ThermAffyx™ System combines air-free patient warming with securement technology to help prevent both hypothermia and patient movement during procedures where it is common for the patient to be positioned in Trendelenburg. Trendelenburg is a tilted, head-down position that uses gravity to shift organs in the abdomen out of the way, giving the surgeon better access. In surgical settings, inadvertent hypothermia can dramatically increase the risk of surgical complications.

“Gentherm engineers began development after identifying this unmet clinical pain point and gap in the market,” confirmed Steve Fletcher, Senior Vice President and General Manager, Gentherm Medical. “Until now, there hasn’t been an all-in-one product that successfully resolves these patient safety concerns. Our innovation will define a new standard of care and improve patient outcomes.”

This is the newest example of the company leveraging technology from its well-known automotive division to develop new systems for medical use.

"This concept is very intuitive and an exciting opportunity for those of us who spend so much time in operating rooms," says Dr. Perrin Jones, an anesthesiologist in North Carolina. "Taking the technology Gentherm uses in heated seats in cars and adapting it into a medical device that we can put under patients to help them stay warm and secure during surgery, will be a game changer in any operating room."

FDA clearance is expected within the first half of 2026.

Investor Contact 
Gregory Blanchette
investors@gentherm.com  
248.308.1702

Media Contact 
Melissa Fischer 
media@gentherm.com   
248.289.9702 

About Gentherm 
Gentherm (NASDAQ: THRM) is a global market leader of innovative thermal management and pneumatic comfort technologies. Automotive products include Climate Control Seats (CCS®), Climate Control Interiors (CCI™), Lumbar and Massage Comfort Solutions, and Valve Systems. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has more than 14,000 employees in facilities across 13 countries. In 2024, the company recorded annual sales of approximately $1.5 billion and secured $2.4 billion in automotive new business awards. For more information, go to www.gentherm.com.

FAQ

What did Gentherm (THRM) announce on February 3, 2026 about ThermAffyx?

Gentherm announced it submitted a 510(k) Class II premarket notification for ThermAffyx. According to the company, ThermAffyx is an integrated air-free warming and securement system targeting intraoperative hypothermia and patient movement.

When does Gentherm (THRM) expect FDA clearance and market launch for ThermAffyx?

Gentherm expects FDA clearance within the first half of 2026 and a market launch in Q3 2026. According to the company, those timelines reflect current regulatory expectations but remain subject to FDA review.

How does the ThermAffyx system aim to improve patient safety in robotic surgery?

ThermAffyx combines air-free patient warming with securement to reduce hypothermia and inadvertent movement. According to the company, this design targets risks when patients are positioned in Trendelenburg during robotic procedures.

Does the ThermAffyx announcement include financial details for Gentherm (THRM)?

No, the announcement does not provide revenue, guidance, or pricing information for ThermAffyx. According to the company, the release focuses on regulatory submission and planned market timing rather than financial metrics.

What technology did Gentherm adapt for the ThermAffyx medical device (THRM)?

Gentherm adapted thermal technology used in automotive heated seats into an under-patient warming and securement system. According to the company, this cross-industry adaptation is central to ThermAffyx’s design and function.